rusfertide

Peptide

Also known as TAK-121

Approvedregulatory verdict

Evidence outlook

Approved: Polycythemia Vera (label: Erythrocytosis in adults with polycythemia vera)

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Polycythemia Vera
Phase 2 (7)
Polycythemia Vera
NCT07648030 · Takeda
2026-07-14 – 2030-05-17 · Polycythemia Vera
What this study did
NCT07765602 · Takeda
2027-03-01 – 2028-08-01 · Polycythemia Vera
What this study did
NCT04057040 · Protagonist Therapeutics, Inc.
2019-10-01 – 2024-06-17 · Polycythemia Vera
What this study did
NCT04767802 · Protagonist Therapeutics, Inc.
2021-02-02 – 2023-03-15 · Polycythemia Vera
What this study did
Other / comorbidity
NCT04202965 · Protagonist Therapeutics, Inc.
2020-03-19 – 2022-02-15 · Hereditary Hemochromatosis
What this study did
NCT04054921 · Protagonist Therapeutics, Inc.
2019-05-10 – 2020-07-31 · β-thalassemia, Ineffective Erythropoiesis
What this study did
NCT03802201 · Protagonist Therapeutics, Inc.
2018-12-19 – 2020-07-31 · β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia
What this study did
Phase 1 (1)
Other / comorbidity
NCT04516382 · Protagonist Therapeutics, Inc.
2020-09-14 – 2021-06-30 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Polycythemia Vera: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rusfertide: this drugApprovedPeptideFerroportinReliable signal
NCT05210790: Response in weeks 20 to 32 (Part 1a): rusfertide 76.9% (n=147) vs placebo 32.9% (n=146), odds ratio 6.42 (95% CI 3.81 to 10.80), p<0.0001 (CT.gov posted results).
Ropeginterferon Alfa-2b (Besremi)ApprovedProtein / enzyme therapeuticType I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Ruxolitinib (Jakafi)ApprovedSmall moleculeJAK1/2Partial signal
NCT01243944: The Percentage of Participants Achieving a Primary Response at Week 32 (32 Weeks): Ruxolitinib 22.7 percentage of participants (95% CI 15.3 to 31.7) | Best Available Therapy 0.9 percentage of participants (95% CI 0 to 4.9)
GivinostatPhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 2Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow rusfertide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2Polycythemia VeraRecruiting
Est. primary completion 2027-10-28 · NCT07648030 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 2Polycythemia VeraNot yet recruiting
Est. primary completion 2028-07-01 · NCT07765602 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 March 2026Filing acceptedFDA accepts rusfertide NDA
US, FDA · Protagonist Therapeutics · Source ↗
2 March 2026Priority reviewRusfertide NDA under Priority Review
US, FDA · Protagonist Therapeutics · Source ↗
3 March 2025Topline resultPhase 3 VERIFY topline
Protagonist Therapeutics · Source ↗